Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma

NCT02487017 is registered in ClinicalTrials.gov with Shenzhen Hornetcorn Bio-technology Company, LTD as lead sponsor.

NCT NCT02487017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02487017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma
Lead sponsor
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2015
Completion date
December 31, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system neoplasms, hepatocellular carcinoma, neoplasms